|drug3815||blood sampling Wiki||0.41|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The PREPARE-IT trial is a simple, pragmatic and universally applicable strategy with icosapent ethyl (IPE) at high doses intended to reduce infection rate and subsequent morbidity and mortality among subjects at high risk of infection due to COVID-19.
Description: SARS-CoV-2 positive subjects are defined as subjects with positive tests for SARS-CoV-2 RT-PCR or for SARS-CoV-2 lgG antibodies after developing COVID-19 disease at any stage within the follow-up period (including those subjects with or without symptomatic COVID-19 evaluated before the final visit) or those individuals who test positive for SARS-CoV-2 RT-PCR or for SARS-CoV-2 lgG antibodies at the final visit (day 60).Measure: Percentage of SARS-CoV-2 positive subjects Time: 60 days
Description: Mean change from baseline will be computedMeasure: Total cholesterol, LDL, HDL, triglycerides (mg/dL) at baseline and at day 60 Time: baseline, 60 days
Description: Mean change from baseline will be computedMeasure: Ultrasensitive C-reactive Protein (mg/dL) at baseline and at day 60 Time: baseline, 60 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports